180 related articles for article (PubMed ID: 36532308)
1. Impact and the delivery of loco-regional treatment for hepatocellular carcinoma during the COVID-19 pandemic.
How GY; Pua U
J Interv Med; 2022 Nov; 5(4):180-183. PubMed ID: 36532308
[TBL] [Abstract][Full Text] [Related]
2. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area.
Amaddeo G; Brustia R; Allaire M; Lequoy M; Hollande C; Regnault H; Blaise L; Ganne-Carrié N; Séror O; Larrey E; Lim C; Scatton O; El Mouhadi S; Ozenne V; Paye F; Balladur P; Dohan A; Massault PP; Pol S; Dioguardi Burgio M; Vilgrain V; Sepulveda A; Cauchy F; Luciani A; Sommacale D; Leroy V; Roudot-Thoraval F; Bouattour M; Nault JC;
JHEP Rep; 2021 Feb; 3(1):100199. PubMed ID: 33163949
[TBL] [Abstract][Full Text] [Related]
3. Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.
Micali C; Russotto Y; Caci G; Ceccarelli M; Marino A; Celesia BM; Pellicanò GF; Nunnari G; Venanzi Rullo E
Infect Dis Rep; 2022 Jan; 14(1):43-55. PubMed ID: 35076514
[TBL] [Abstract][Full Text] [Related]
4. Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma.
Zane KE; Nagib PB; Jalil S; Mumtaz K; Makary MS
World J Hepatol; 2022 May; 14(5):885-895. PubMed ID: 35721283
[TBL] [Abstract][Full Text] [Related]
5. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma.
Wu TH; Wang YC; Cheng CH; Lee CF; Wu TJ; Chou HS; Chan KM; Lee WC
World J Gastrointest Surg; 2020 Jan; 12(1):17-27. PubMed ID: 31984121
[TBL] [Abstract][Full Text] [Related]
6. Loco-regional intervention for hepatocellular carcinoma.
Lau WY; Lai ECH
J Interv Med; 2019 May; 2(2):43-46. PubMed ID: 34805870
[TBL] [Abstract][Full Text] [Related]
7. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates.
Keng GH; Sundram FX; Yu SW; Somanesan S; Premaraj J; Oon CJ; Kwok R; Htoo MM
Ann Acad Med Singap; 2002 May; 31(3):382-6. PubMed ID: 12061301
[TBL] [Abstract][Full Text] [Related]
8. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
Poon RT; Fan ST; Tsang FH; Wong J
Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
[TBL] [Abstract][Full Text] [Related]
9. Management of hepatocellular carcinoma.
Fitzmorris P; Shoreibah M; Anand BS; Singal AK
J Cancer Res Clin Oncol; 2015 May; 141(5):861-76. PubMed ID: 25158999
[TBL] [Abstract][Full Text] [Related]
10. Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations.
Fancellu A; Sanna V; Scognamillo F; Feo CF; Vidili G; Nigri G; Porcu A
World J Clin Cases; 2021 May; 9(15):3517-3530. PubMed ID: 34046452
[TBL] [Abstract][Full Text] [Related]
11. Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities.
Rossi SM; Murray T; McDonough L; Kelly H
Expert Opin Drug Deliv; 2021 May; 18(5):607-623. PubMed ID: 33253052
[No Abstract] [Full Text] [Related]
12. Value of subtraction MRI in assessing treatment response following image-guided loco-regional therapies for hepatocellular carcinoma.
Winters SD; Jackson S; Armstrong GA; Birchall IW; Lee KH; Low G
Clin Radiol; 2012 Jul; 67(7):649-55. PubMed ID: 22300821
[TBL] [Abstract][Full Text] [Related]
13. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
14. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey.
Huo T; Huang YH; Wu JC; Chiang JH; Lee PC; Chang FY; Lee SD
Aliment Pharmacol Ther; 2004 Jun; 19(12):1301-8. PubMed ID: 15191512
[TBL] [Abstract][Full Text] [Related]
15. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review.
Schipilliti FM; Garajová I; Rovesti G; Balsano R; Piacentini F; Dominici M; Gelsomino F
Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33429973
[TBL] [Abstract][Full Text] [Related]
16. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies.
Haubold J; Reinboldt MP; Wetter A; Li Y; Ludwig JM; Lange C; Wedemeyer H; Schotten C; Umutlu L; Theysohn J
Rofo; 2020 Sep; 192(9):862-869. PubMed ID: 32131109
[TBL] [Abstract][Full Text] [Related]
17. Loco-regional treatment of HCC: current status.
Crocetti L; Bargellini I; Cioni R
Clin Radiol; 2017 Aug; 72(8):626-635. PubMed ID: 28258743
[TBL] [Abstract][Full Text] [Related]
18. Impact of the Early COVID-19 Pandemic on Incidence and Outcomes of Hepatocellular Carcinoma in the United States.
Liang J; Lee YT; Yeo YH; Luu M; Ayoub W; Kuo A; Trivedi H; Vipani A; Gaddam S; Kim H; Wang Y; Rich N; Kosari K; Nissen N; Parikh N; Singal AG; Yang JD
Clin Transl Gastroenterol; 2024 Jun; ():. PubMed ID: 38829967
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for hepatocellular cancer.
Singh G; Yoshida EM; Rathi S; Marquez V; Kim P; Erb SR; Salh BS
World J Hepatol; 2020 Sep; 12(9):558-573. PubMed ID: 33033565
[TBL] [Abstract][Full Text] [Related]
20. Interventional radiology approaches for intra-hepatic cholangiocarcinoma.
Mosconi C; Calandri M; Javle M; Odisio BC
Chin Clin Oncol; 2020 Feb; 9(1):8. PubMed ID: 32008330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
